Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeeking Alpha • 09/06/25
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IIPRNewsWire • 09/05/25
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIPRNewsWire • 08/18/25
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 08/07/25
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic RetinopathyPRNewsWire • 08/07/25
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 07/31/25
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular DystrophyPRNewsWire • 07/10/25
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerBenzinga • 06/05/25
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202PRNewsWire • 06/05/25
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202PRNewsWire • 06/02/25
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionPRNewsWire • 05/19/25
FDA Accepts Biologics License Application for Mucopolysaccharidosis II TreatmentPRNewsWire • 05/14/25
REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS IIPRNewsWire • 05/13/25
REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational HighlightsPRNewsWire • 05/12/25
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual MeetingPRNewsWire • 05/08/25
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 05/05/25
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational HighlightsPRNewsWire • 04/30/25
REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPYPRNewsWire • 03/19/25